Biointegrated Battery‐Based Electroceuticals Authors: Yan Zhou, Zhilian Yue, Zhiqi Chen, Danming Chao, Xiaoteng Jia, Gordon Wallace, Caiyun Wang Published: 2026 ABSTRACT ABSTRACTBiointegrated batteries offer innovative technological platforms for tissue regeneration and disease treatment. Beyond serving as a power source for medical devices, they actively contribute to therapy by generating localized electric fields (EFs) and releasing therapeutically beneficial products. Accordingly, biointegrated batteries support a wide range of biomedical applications, including tissue regeneration, cancer therapy, cardiac pacing, and drug delivery. This review offers an overview of the recent advances in biointegrated battery‐based electroceuticals, emphasizing their applications in electrostimulation, electrochemical product‐mediated therapy, and drug delivery. This review provides a brief overview of the working principles of battery‐based electrocatalysts, focusing on their therapeutic mechanisms and highlighting their unique contributions in advancing disease treatment strategies. Finally, we discuss the future directions and provide insights into the broad adoption of battery‐based electroceutical technologies in next‐generation biomedical therapeutics.Keywords: biointegrated batteries, electroceuticals, interfaces, medical devices, therapeutic technology Introduction Personalized medical devices have evolved from general therapeutic tools to precise health‐management platforms [1, 2, 3]. The rapidly expanding field of medical devices encompasses a wide range of technologies [4, 5], including biosensors [6], smart drug delivery systems [7], bioelectronic chips [8], pacemakers [9], and cochlear implants [10], offering powerful capabilities for disease diagnosis, monitoring, and targeted intervention [11]. Currently, miniaturizing personal medical devices is constrained by their dependence on conventional energy systems, such as lithium, alkaline, and solid‐state batteries [12, 13]. The stringent encapsulation required to contain the toxic electrolytes, electrode materials, and associated battery byproducts restrict device miniaturization. Furthermore, energy systems are integrated with complex therapeutic systems, which substantially increases system complexity and cost [14]. Such constraints have driven the emergence of next‐generation batteries that supply power as well as actively participate in disease treatment [15]. Batteries designed for direct implantation or intimate integration with the human body are referred to as biointegrated batteries. Battery‐based electrocatalysts exemplify this paradigm by intrinsically embedding therapeutic functionalities into energy systems. Conventional medical devices often suffer from mechanical mismatch with soft biological tissues, which can lead to foreign‐body reactions, fibrous encapsulation, and infection risk [16]. In parallel, traditional pharmacotherapies are limited by off‐target toxicity, systemic side effects, and poor spatiotemporal control, particularly in achieving precise drug delivery within the pathological microenvironment [17]. In contrast, biointegrated batteries represent a fundamental paradigm shift in medical devices, transitioning from passive implants to autonomous, self‐powered electroceutical platforms [18]. They convert stored chemical energy into localized and controllable therapeutic outputs, enabling integrated, on‐demand, multidimensional intervention directly at the lesion site. Biointegrated batteries demonstrate superiority over traditional clinical therapies in terms of improved spatial precision, enhanced in vivo biosafety, and the ability to dynamically remodel the pathological microenvironment [19, 20]. Biointegrated batteries have been increasingly developed for medical applications because of their ability to safely interact with living tissues without causing harmful reactions [21]. Beyond their traditional role as power sources, these systems interact directly with biological systems, leveraging in situ electrochemical reactions to actively modulate disease treatment processes or enable controlled therapeutic agent release, enabling new opportunities for next‐generation bioelectric medicine [22]. Recent works have demonstrated the efficacy of biointegrated batteries in wound healing, bone regeneration, nerve repair, cardiac pacing, and tumor suppression. By enabling the precise and multidimensional regulation of cell behavior, these systems advance therapeutic intervention (Figure 1). Electric fields (EFs) generated during battery discharge modulate cell membrane permeability, activate voltage‐gated ion channels, and influence cellular metabolism and fate [23]. Concurrently, EFs regulate cellular electrophysiological behavior and signal transduction through controlled gene expression and hormone or neurotransmitter synthesis [24]. Moreover, the electrochemical byproducts generated during battery operation (e.g., reactive oxygen species (ROS), gases, and metal ions) exhibit concentration‐dependent biological effects [25]. Furthermore, EFs activate cell signaling pathways and support normal metabolism; however, excessive accumulation may induce apoptosis or programmed cell death [26]. Therefore, precise control of battery byproduct dosage is crucial for achieving targeted therapy. Additionally, biointegrated batteries can be engineered to deliver drugs directly via iontophoresis and electroosmosis [27]. In view of the rapid advances in this field, a comprehensive review is timely and necessary to inform future research directions and accelerate clinical translation. Biointegrated batteries as active therapeutic platforms for biomedical intervention. These systems enable four interconnected functions: reliable power supply for wearable and implantable bioelectronic devices, biomimetic interface for conformal tissue integration and efficient signal transmission, electrical stimulation (ES) for biophysical cellular behavior modulation, and electrochemical byproducts for localized biochemical interventions and pathological microenvironment modulation. Created in BioRender. Zhou, Y. (2026) https://BioRender.com/048gj68. Existing reviews have primarily focused on high‐performance batteries and energy‐conversion strategies for powering bioelectronics, emphasizing material design, galvanic cell chemistry, and device engineering to enhance power output and functional performance for translational applications [28, 29, 30, 31]. In contrast, this review focuses on biointegrated batteries with therapeutic functions to provide an in‐depth analysis of the inherent logic that redefines disease therapeutic paradigms. This review systematically presents a conceptual framework for biointegrated batteries as electrocatalysts, with the aim of bridging the gap between energy technologies and active biomedical interventions. After outlining the design principles of the electrodes and electrolytes, we elucidate the synergistic intervention mechanisms of this battery system as a microtherapeutic platform. This strategy utilizes the multimodal synergistic effects of the physical EFs generated by battery discharge and active therapeutic agents produced by electrochemical reactions to achieve precise intervention. By tracing the development path from the fundamental mechanisms of biointegrated batteries to regulated clinical device commercialization, this review aims to provide key perspectives to promote interdisciplinary collaboration and accelerate clinical translation. Biointegrated Battery‐Based Electroceuticals Biointegrated batteries are designed to operate in intimate contact with living tissues. Unlike traditional passive electronic devices, they function as active therapeutic platforms and therefore must meet stringent biomedical and electrochemical requirements [32]. First, mechanical adaptability is essential for maintaining conformal contact and stable electrical coupling with dynamically deformed tissues [33] (Figure 2a). Second, all battery materials and their electrochemical byproducts must exhibit excellent biocompatibility. Controlled biodegradation, which involves complete degradation and safe clearance from the body via natural metabolic pathways after electrotherapy, can minimize long‐term foreign body reactions and immune rejection (Figure 2b) [34, 35]. Third, implantable systems also require miniaturization with sufficient energy density to satisfy spatial constraints while supporting sustained therapeutic operation (Figure 2c) [36]. Fourth, long‐term interfacial stability and effective electrical communication are critical, as biofluids rich in proteins and reactive species can induce surface passivation and hinder ion/electron transport (Figure 2d). Therefore, electrode–electrolyte and electrode–tissue interfaces must be engineered to resist biofouling, maintain stable ion transport, and ensure sustained electrical communication with surrounding tissue [37]. To address these challenges, current strategies integrate advanced electrode materials, including metals (e.g., Zn, Mg, Fe, Mo, and Na) and their alloys, conductive polymers, or carbon‐based materials [38, 39, 40, 41, 42, 43, 44, 45, 46] with engineered electrolytes (e.g., hydrogels and body fluids) [47, 48, 49, 50, 51, 52, 53, 54, 55, 56]. Additionally, advanced microfabrication techniques (e.g., magnetron sputtering, 3D printing, screen printing, and vacuum deposition) [57, 58, 59, 60] further enable the development of reliable and high‐performance biointegrated batteries under physiological conditions. Design paradigms and biomedical applications of biointegrated batteries. (a) Mechanical adaptation: Schematics and representative photographs of a flexible all‐hydrogel battery enabling conformal integration with dynamic tissues, ensuring stable power output under deformation. Reproduced with permission [33, 61]. Copyright 2021, Ye and 2024, Gao, published by John Wiley and Sons. (b) Biocompatibility: Schematic illustrating cell–material interactions on battery substrates and comparative in vivo studies demonstrating improved tissue recovery and reduced inflammatory response for hydrogel‐based battery architectures compared with conventional lithium‐based systems [48]. Copyright 2024, Liu, published by John Wiley and Sons. (c) Miniaturization: Advanced engineering design of a millimeter‐scale, phototransistor‐driven pacemaker, illustrating the potential for seamless power unit integration with micro‐scale therapeutic devices. Reproduced with permission [62]. Copyright 2025, Zhang, published by Springer Nature. (d) Efficient bioelectric communication: Schematics and representative images of low‐impedance electrode–tissue interface. The system leverages Mg/FeMn‐based electrodes for efficient charge injection and high‐fidelity signal recording across sciatic nerve gaps, facilitating neuro‐regeneration and electroceutical therapy. Reproduced with permission [63]. Copyright 2025, Wang, published by Springer Nature. Created in BioRender. Zhou, Z. (2026) https://BioRender.com/048gj68. Biointegrated batteries enable multidimensional and cross‐scale therapeutic modulation via engineered electrochemical processes [64]. By precisely controlling electrode kinetics and interfacial mass transport in confined physiological environments, they generate sustained therapeutically endogenous EFs together with electrochemically active species (e.g., ROS, gases, and metal ions). These coupled outputs modulate cellular transmembrane potentials and electrophysiological rhythms while simultaneously disrupting abnormal local ionic homeostasis at the lesion site, thereby dynamically reshaping the pathological microenvironment. This approach establishes a foundation for in situ tissue electrotherapy and immunometabolic microenvironment regulation (Figure 3a,b). In addition, these batteries leverage potential gradients or ionic fluxes to trigger stimulus‐responsive release of drug carriers, enabling sequential and programmable delivery of therapeutic agents. Biointegrated batteries can function as integrated power sources for on‐demand pharmacological interventions (Figure 3c). This integrated functionality extends their role beyond conventional energy supply, establishing biointegrated batteries as a unified electroceutical platform that integrates energy delivery with active therapeutic interventions. As an emerging electroceutical platform, biointegrated battery systems offer capabilities beyond conventional therapies, enabling efficient tissue regeneration, precise pathological microenvironment remodeling, and programmable drug delivery. The following section systematically reviews the recent advances in biointegrated battery‐based electroceuticals for disease therapy, highlighting their roles in electrotherapy, microenvironmental regulation therapy, and pharmacotherapy. Therapeutic mechanisms of biointegrated batteries. (a) Electrotherapy: battery‐generated electric fields (EFs) biophysically regulate cell behavior, program cell fate, and modulate cellular electrophysiology. (b) Microenvironment remodeling: electrochemical byproducts modulate pathological microenvironment via energy deprivation, local immune response modulation, and intracellular metabolic intervention. (c) Pharmacotherapy: biointegrated batteries electrochemically trigger drug release and power drug‐delivery devices. Biointegrated Batteries for Localized Electrotherapy Biointegrated batteries convert chemical energy into electrical energy through internal electrochemical reactions, generating a stable potential difference that enables controlled external EF delivery [65]. The applied EF induces fundamental biochemical changes at the molecular level via physical forces (e.g., electrophoresis and electroosmosis) (Figure 4a). These physical effects directly regulate cellular behavior and guide directional cell migration via galvanotaxis to support tissue repair and regeneration [66]. To elucidate the subcellular pathways underlying these macroscopic cellular behaviors, Figure 4b summarizes electrical stimulation (ES)‐associated cellular response mechanisms. At the cellular level, the EF modulates transmembrane ion transport (e.g., Ca2+, Na+, and K+ fluxes) and induces dynamic cell membrane component rearrangement. The associated Faraday processes drive the local redox reactions in the extracellular microenvironment. ES also enhances mitochondrial adenosine triphosphate (ATP) production during tissue repair [67]. These coordinated biophysical and biochemical signals subsequently activate cytokine receptors on the cell surface and downstream signaling pathways, ultimately achieving precise regulation of gene expression [64]. The aforementioned cascade outlines a general paradigm for ES‐induced cellular responses, which has also been validated in biointegrated battery systems. Collectively, biointegrated batteries have demonstrated therapeutic potential in regenerative medicine, including applications in wound healing, nerve regeneration, bone repair and regeneration, and cardiac therapy. Therapeutic mechanisms and clinical applications of EFs generated by biointegrated batteries. (a) Biophysical modulation at molecular and cellular levels. EFs direct the transport of charged biomolecules via electrophoresis and electroosmosis, thereby regulating cellular behavior and fate [90]. Copyright 2024, Huang, published by The Royal Society of Chemistry. (b) Intracellular response mechanisms. Biointegrated batteries trigger a series of intracellular events via applied EF and localized Faradaic currents. (c) Accelerated wound healing. EFs promote wound healing by mimicking endogenous trans‐epithelial potentials and modulating immune responses. (d) Guided neural repair. EFs stimulate Schwann cell migration and neurotrophic factor secretion, promoting axonal growth and partially damaged nerve fiber remyelination. (e) Bone regeneration. EFs alter the membrane potential of osteoblasts, triggering intracellular Ca2+ transients and spatial membrane receptor redistribution, which together optimize the osteogenic microenvironment to accelerate defect repair. (f) Cardiac pacing and defibrillation. Biointegrated batteries directly regulate cardiac action potentials by driving transmembrane ion exchange in cardiomyocyte membranes, providing reliable, wireless rhythmic ES to correct arrhythmias. Created in BioRender. Zhou, Y. (2026) https://BioRender.com/048gj68. Biointegrated Battery‐Enabled Active Wound Management When the skin is damaged, the normal transepithelial potential (10–60 mV) at the wound site is disrupted, leading to endogenous EF formation from the surrounding healthy tissue toward the wound site. Endogenous EF plays a critical role in wound healing by promoting fibroblast proliferation, guiding epidermal cell migration, and enhancing the responsiveness to growth factors by regulating receptor activity [68]. The stable EF generated between the anode and cathode of a biointegrated battery drives charge carriers (ions/electrons) to migrate via electrochemical reactions, thereby promoting wound healing by mimicking the natural bioelectric field of the body (Figure 4c). For instance, Zn–Ag and Zn–Cu batteries fabricated by magnetron sputtering or screen printing technology accelerate wound healing by generating a continuous, stable EF between the electrodes [69, 70]. EFs enhance wound repair by activating cell function, promoting cell migration and proliferation, modulating cell metabolism and signal transduction pathways (e.g., secretion and release of key growth factors), and regulating the local microenvironment. Chen et al. integrated a flexible rechargeable zinc─manganese dioxide (Zn─MnO2) battery with a loop circuit to achieve excellent electrochemical performance and effective wound healing [71]. However, the need for external charging and use of metal‐wire stimulation electrodes limit their portability and autonomous operation. Recently, we introduced a wearable electrotherapy patch for chronic wound healing, in which electrodes simultaneously participate in electrochemical reactions and act as stimulation sites. In this design, a conductive hydrogel cathode was placed directly on the wound, and a Zn or Mg anode was adjacently positioned. Conductive hydrogel electrodes with a high‐water content and moderate conductivity minimize local heating effects and prevent cellular and tissue damage. Notably, batteries with conducting polymer hydrogel cathodes (viologen‐ or poly(3,4‐ethylenedioxythiophene)‐based [PEDOT‐based] hydrogels) utilize oxygen to self‐charge. This capability extends battery service life and reduces the need for battery replacement during disease treatment [72, 73, 74]. Beyond patch‐type designs, tubular Mg─Mo and Mg‐based fiber batteries have also been designed to enhance wound healing with excellent tissue conformability. Biointegrated battery‐based wound treatment technologies have recently progressed from epidermal applications to in vivo postoperative healing. For example, electronic dressings combining Mg─Mo batteries with nanoelectroporation technology have significantly reduced postsurgical complications in the intestines. This system provides both direct current (DC) and alternating current (AC) dual‐mode ES, synergistically accelerating intestinal wound healing [75]. Biointegrated batteries have emerged as a promising technology for wound healing owing to their unique electrochemical regulation capabilities. Recent advances in interdisciplinary research have accelerated intelligent wound management device development that integrates biointegrated batteries with sensors for the real‐time monitoring and dynamic adjustment of ES. Gao et al. designed a wearable bioelectronic system that integrates electrochemical biosensors to monitor wound conditions and adjust ES, thereby promoting tissue regeneration [76, 77]. Biointegrated batteries are poised to play an important role in clinical applications, especially in rechargeable systems with controllable degradation properties for treating chronic wounds and supporting long‐term healing processes. Biointegrated Battery‐Derived ES for Nerve Regeneration Sustained EFs generated by biointegrated batteries promote neural regeneration at both cellular and tissue levels. At the cellular level, EFs can enhance Schwann cell proliferation and efficient secretion of nerve growth factors, providing critical nutritional support for neuronal survival and axonal outgrowth. They also upregulate microtubule‐associated protein‐2 and Schwann cell marker S100 calcium‐binding protein B (S100B) expression and increase axonal branching and elongation. At the tissue level, EFs stimulate in vivo myelin basic protein and S100B synthesis within the living microenvironment, thereby accelerating the myelination and functional recovery in damaged peripheral nerves [78, 79]. With the comprehensive restoration of structural reconstruction and neurophysiological function, this intervention reversed the muscle atrophy caused by denervation and inhibited muscle fibrosis. Notably, biointegrated batteries enable localized stimulation with minimal damage to surrounding tissues, offering clear advantages over conventional rigid neural interfacing devices. Fibrous and tubular batteries facilitate intimate contact with neural tissue, reducing interface impedance and enhancing electrical signal transmission efficiency. A notable example is the tubular Zn battery developed by Zhang et al., which provides in situ ES for nerve regeneration (Figure 4d). The battery serves as a nerve conduit, effectively promoting long‐segment injured sciatic nerve regeneration [80]. Similarly, Yin et al. developed a biodegradable tubular battery using Mg and Fe─Mn electrodes for peripheral nerve regeneration. The tubular structure conforms to that of the nerve and accelerates sciatic nerve regeneration [81]. In addition, this team further developed biodegradable Zn─Mo batteries that directly interface with damaged nerves and deliver sustained therapeutic EF, thereby promoting nerve regeneration and functional recovery [82]. Beyond conventional sealed metal batteries, body‐fluid‐activated batteries generate localized ES at target sites, enabling precise damaged nerve tissue treatment [83]. Biointegrated Battery‐Driven Bone Regeneration Biointegrated batteries generate localized therapeutic EFs that serve as key biophysical interventions to promote bone repair and regeneration. These EFs utilize the galvanotaxis effect to efficiently guide bone marrow mesenchymal stem cells (BMSCs) and macrophages toward the defect sites. They also promote macrophage polarization toward the anti‐inflammatory M2 phenotype, establishing a favorable osteogenic microenvironment. At the subcellular and molecular levels, EFs alter membrane potential and activate voltage‐gated calcium channels, inducing intracellular calcium ion (Ca2+) influx [84]. The resulting Ca2+ signaling acts as a second messenger to activate key osteogenic and pro‐survival pathways, including Wingless‐related integration site/β‐catenin, bone morphogenetic protein/Smad, and phosphoinositide 3‐kinase/protein kinase B, collectively supporting bone regeneration. These pathways upregulate the expression of key osteogenic markers, including alkaline phosphatase, osteopontin, osteocalcin, and type I collagen, accelerating extracellular matrix synthesis and hydroxyapatite mineralization and deposition [85]. Non‐invasive devices, such as the EBI Bone Healing System, have been approved for treating fractures, failed joint fusion, and congenital tibial pseudarthrosis [86]. Recently, flexible biointegrated batteries have emerged as promising platforms for bone regeneration owing to their safety, implantability, and customizable design. Their mechanical flexibility allows conformal integration with complex bone defects. Both Zn‐ and Mg‐based batteries effectively promote bone repair. For example, Wang et al. developed an implantable Zn‐ion battery consisting of a gelatin/polycaprolactone composite gel electrolyte, MnO2 cathode, and electroplated Zn anode encapsulated within a polyvinyl alcohol/carboxymethyl cellulose composite membrane. The synergistic effects of controlled release of Zn2+ and EF stimulation significantly enhance osteogenesis‐related factor expression and accelerate BMSC differentiation into osteoblasts (Figure 4e) [87]. Although biointegrated batteries are a promising therapeutic option for bone regeneration, their clinical translation remains challenging owing to issues such as electrochemical stability, interface stability, and slow degradation. Biointegrated Batteries for Cardiac Rhythm Management Biointegrated batteries serve as essential power sources for implantable cardiac electronic devices that support pacing and defibrillation. In pacing applications, these devices supply low‐voltage currents that are precisely modulated by integrated microelectronics to generate temporally controlled, low‐amplitude electrical pulses. These pulses elicit localized depolarization of cardiomyocytes, initiating and propagating action potentials that restore normal rhythmic contractions (Figure 4f). For instance, Rogers and Zhang (year) developed the smallest pacemaker in the world by integrating a microbattery and a photodetector within biological tissue. In this design, the battery electrodes function directly as pacing electrodes, whereas bodily fluids serve as electrolytes, enabling self‐powered operation after implantation [62]. Similarly, He et al. engineered a biodegradable hydrogel battery capable of supporting both microcurrent‐induced tissue regeneration and high‐current‐activated cardiac pacing [88]. In the context of life‐threatening arrhythmias, such as ventricular fibrillation, biointegrated batteries are designed to rapidly deliver high‐current outputs to charge high‐voltage capacitors, which are subsequently discharged to induce synchronized depolarization of a critical mass of myocardial tissue. This process effectively terminates chaotic electrical activity and allows the sinoatrial node to resume its natural pacing function. Representative advances include a microscale flexible Li ion (Li+) droplet battery for cardiac defibrillation fabricated using lipid‐supported droplet assembly technology [89]. By enabling dual‐energy delivery modes, sustained low‐power output for pacing, and high‐power transient pulses for defibrillation, biointegrated batteries underpin the therapeutic efficacy of modern implantable cardiac devices and play a critical role in clinical cardiology. Biointegrated Battery‐Enabled Microenvironment Remodeling for Precise in situ Therapy Biocompatible metal electrode‐based biointegrated batteries (e.g., Zn and Mg) generate bioactive products in situ during discharging, including ROS intermediates, gas molecules, and metal ions. Byproduct formation depends on the electrode material, electrolyte, and reaction conditions. Within appropriate concentration ranges, biointegrated batteries exert significant biological effects, such as promoting tissue regeneration, regulating the cellular microenvironment, activating immune responses, and suppressing pathogenic microorganism proliferation (Figure 5). This section reviews recent biomedical applications of battery byproducts, with an emphasis on their dynamic regulatory roles in the cellular microenvironment. Therapeutic electrochemical byproducts generated from biointegrated batteries. (a) Reactive oxygen species (ROS)‐mediated microenvironmental modulation. Electrochemical reaction‐generated ROS induce targeted oxidative stress in pathological cells. Excessive ROS accumulation disrupts mitochondrial function, leading to reduced adenine triphosphate (ATP) synthesis, cytochrome C release, and mitochondrial DNA (mtDNA) leakage. (b) Precision gas therapy via in situ therapeutic gas generation for cellular intervention. For example, free radical scavenging and lipid peroxidation (LPO) inhibition regulate cytokine, ATP, and heat shock protein (HSP) expression while activating specific receptors (e.g., peroxisome proliferator‐activated receptor γ, [PPAR‐γ]) stimulates downstream signaling. (c) Targeted metalloimmunotherapy. Controlled electrode electrolysis enables localized bioactive metal ion release, which activates both innate and adaptive immune responses through three classical pathways. Toll‐like Receptor (TLR) signaling: Metal ions activate TLR4, triggering the inhibitor of kappa B kinase /nuclear factor‐κB (IKK/NF‐κB) cascade to release pro‐inflammatory cytokines. NLR signaling: The influx of metal ions leads to increased levels of mitochondrial reactive oxygen species (mtROS) and mtDNA, triggering apoptosis and upregulating cytokines (e.g., interleukin‐1β [IL‐1β] and interleukin‐18 [IL‐18]). STING pathway: Metal ions activate the cyclic guanine monophosphate (cGMP)–adenosine monophosphate synthase (cGAS)–stimulator of interferon genes (STING) signaling pathway, promoting type I interferon (IFN‐I) production. Electrochemical Modulation of Pathological Microenvironments ROS are a group of highly reactive oxygen molecules, including superoxide anion (O2•−), hydrogen peroxide (H2O2), and hydroxyl radical (·OH). ROS play crucial roles in maintaining cellular functions, regulating signal transduction, and enhancing immune responses [91]. However, excessive ROS accumulation induces oxidative stress, causing cellular damage by attacking biomolecules, such as proteins, lipids, and nucleic acids within the cells. To maintain the dynamic ROS balance, organisms have evolved antioxidant defense systems, including superoxide dismutase, catalase, and glutathione [92]. Understanding the dual role of ROS is crucial for elucidating disease mechanisms and guiding therapeutic development. However, conventional therapies often lack precise control over the spatial and temporal distribution of oxidative stress. In contrast, biointegrated batteries can serve as exogenous, on‐demand ROS generators with high spatiotemporal controllability [93]. Through localized electrochemical processes (e.g., electrode corrosion, oxygen reduction, or electron transfer), they enable site‐specific generation of high‐concentration ROS at the target lesion. This electrochemical strategy is designed to maximize the therapeutic efficacy while minimizing off‐target oxidative damage to surrounding healthy tissues [94]. These features highlight the advantages of biointegrated battery‐mediated ROS generation for treating various diseases. Recent designs have utilized pyridine homologues with tunable peroxide half‐lives as molecular switches to enable programmed ROS release, endowing these batteries with targeted antitumor activity [95]. In another approach, batteries consisting of pyridoxine and specific peptides increased ROS levels in bacteria, causing damage to DNA, proteins, and membranes. Their efficacy was confirmed in a mouse pneumonia model, in which they induced the death of methicillin‐resistant Staphylococcus aureus [96]. Xia et al. developed an oxygen (O2)‐mediated self‐rechargeable Zn‐polyimide battery that continuously regulated oxygen levels, pH, and ROS within the tumor microenvironment during discharge/self‐charging cycles, leading to significant hypoxia‐induced inhibition [97]. Similarly, a Zn‐based self‐charging battery developed by Jia et al. suppresses bacterial proliferation through the ROS generated during battery operation [73]. Metal primary batteries have also been explored for tumor inhibition, in which electrons released from anode corrosion react with biomolecules surrounding the cancer cells to generate highly cytotoxic active substances, enabling efficient chemokinetic treatment [98]. Moreover, electrochemically generated ROS serve as interfaces between electronic devices and engineered living cells. In a proof‐of‐concept study of type 1 diabetes, researchers applied DC through acupuncture needles to generate ROS. They successfully induced genetically engineered cells implanted in diabetic mice to respond to ROS signals, significantly enhancing insulin secretion and effectively regulating blood glucose levels [99]. ROS generated by biointegrated batteries have broad therapeutic potential in antitumor, antibacterial, immunomodulatory, and tissue regeneration. However, their concentrations and release rates must be precisely controlled to maximize their therapeutic benefits while minimizing their cytotoxic effects on healthy tissues. In addition, the non‐specific reactivity of ROS poses a risk to normal cells, making the selective targeting of diseased cells and tissues a key challenge. In Situ Electrochemical Gas Generation for Precision Gas Therapy Gas therapy is a noninvasive treatment strategy widely used in treating and rehabilitating various diseases, including cardiovascular diseases, neurological disorders, and malignant tumors. However, the clinical application of conventional gas therapy is limited by low gas solubility, poor tissue targeting, and uncontrolled release kinetics [100]. Biointegrated batteries address these challenges by utilizing in situ electrochemical reactions to generate therapeutic gases in a controlled manner. Although hydrogen therapy is commonly accepted to exert its antioxidant effects by upregulating the nuclear factor erythroid2‑related factor 2 (Nrf2)/heme oxygenase‑1 signaling pathway and selective ROS scavenging, these biological mechanisms should be distinguished from the device‐specific physicochemical intervention mechanisms enabled by biointegrated batteries [101]. Owing to their unique electrochemical kinetics, device architecture, and released byproducts, biointegrated batteries provide unprecedented spatiotemporal control and synergistic intervention capabilities for localized H2 delivery. (Figure 6) Liu et al. designed a Mg‐based primary nanobattery to disrupt redox homeostasis within cancer cells and induce severe mitochondrial dysfunction via sustained high‐concentration H2 release. The released alkaline by‐products further neutralize the acidic tumor microenvironment, synergistically reversing local immune suppression [102]. In another example, a Zn─Fe primary cell with a tunable H2 release rate, achieved by adjusting the ratio of Zn to Fe, significantly improved insulin resistance and reduced systemic inflammation in obese mice [103]. In addition, the integrated hydrogel network of the electrochemical battery exhibits a unique physical confinement effect on ischemia‐reperfusion (I/R) injury. Its 3D polymer network can physically trap and store electrochemically generated H2 bubbles in situ, effectively preventing the escape of disordered gas. The continuously diffusing and permeating H2 can precisely neutralize locally generated OH radicals during the reperfusion phase, efficiently restoring the electrophysiological conduction and contractile functions of the damaged heart [104]. Mechanism and therapeutic applications of gas‐generating biointegrated batteries for cancer therapy and tissue regeneration. (a) Schematic of a Zn/Mg─O2 battery operating in the tumor microenvironment. The battery utilizes the hypoxic tumor niche to drive in situ H2 generation, facilitating synergistic hydrogen therapy and hypoxia‐activated chemotherapy. Reproduced with permission [105]. Copyright 2025, Dong, published by John Wiley and Sons. (b) Molecular mechanism of H2‐mediated immunogenic cell death (ICD) and cyclic guanosine monophosphate–adenosine monophosphate synthase stimulator of interferon genes (cGAS‐STING) pathway activation. The electrolytically produced H2 triggers mitochondrial DNA (mtDNA) release, which activates the cGAS‐STING signaling axis, enhancing Type I interferon (IFN) production and promoting antitumor immunity. Reproduced with permission. Reproduced with permission [106]. Copyright 2025, Yang, published by John Wiley and Sons. (c) Preparation and clinical application of a microneedle battery‐based H2‐generating patch. This patch modulates the inflammatory microenvironment by scavenging ROS, achieving localized reversal of photoaging wrinkles. Reproduced with permission [107]. Copyright 2025, Lin, published by John Wiley and Sons. (d) Schematic of redox homeostasis disruption and mitochondrial function assessment, showing the impact of electrochemical products on intracellular redox balance and mitochondrial health. Reproduced with permission [102]. Copyright 2022, Yang, published by Springer Nature. In addition to H2, biodegradable Zn─Mo batteries generate nitric oxide (NO) via sodium nitrite electrolysis, which promotes Schwann cell proliferation and neuronal axon growth [108]. NO is a key gas signaling molecule that plays important roles in vasodilation, respiratory disease intervention, immune regulation, and neuroprotection [109]. Battery‐integrated gas therapy offers the advantages of noninvasiveness and portable treatment modalities with broad potential for diseases, such as tumors, ischemia‐reperfusion injury, anti‐inflammatory conditions, and biofilm‐associated infections. Future research should focus on optimizing gas‐release kinetics and improving targeting strategies to maximize therapeutic efficacy while ensuring safety. Biointegrated Battery‐Mediated Metalloimmunotherapy via Ion Delivery Biointegrated batteries have emerged as highly versatile, controllable, and spatiotemporally regulated platforms for metalloimmunotherapy. Through programmable electrochemical reactions, these systems enable the in situ release of bioactive metal ions (e.g., Zn2+, Mg2+, Mn2+, Cu2+, and Li+) for various therapeutic functions, including antimicrobial therapy, tissue regeneration, and neuromodulation [110]. By modulating the electrode composition, device architecture, and operating conditions, the release kinetics and local metal ion release kinetics can be precisely managed, overcoming the systemic toxicity and rapid clearance associated with conventional drug delivery methods. For example, Cheng et al. designed a bodyfluid‐activated Mn─Pt battery that continuously produces H2 and Mn2+ to inhibit tumors by enhancing cyclic guanosine monophosphate adenosine monophosphate synthase–stimulator of the interferon gene (cGAS‐STING) pathway activation [106]. Ding et al. developed a tumor microenvironment‐activated Zn//MnO2 battery that utilizes body fluid electrolyte and glutathione mediator to sustain local Zn2+ and Mn2+ delivery. The battery synergistically induces immunogenic cell death through ROS accumulation and potently activates the STING pathway, achieving exceptional tumor suppression without repeated administration [26]. Similarly, bimetallic copper–tin nanozymes based on the nanoscale galvanic effect have been used to eliminate bacteria and drug‐resistant tumor cells while enhancing antitumor immune responses [111]. In addition to tumor ablation, electrochemically controlled metal‐ion release has demonstrated tremendous potential in tissue engineering and neural modulation. Zn─Ge alloys utilize the eutectic Ge phase to form dense microgalvanic structures that locally release ions while regulating biodegradation, significantly enhancing osteogenic activity [112]. The latest innovation has transformed the classic lithium iron phosphate (LiFePO4) cathode‐based bioelectronic interface, enabling highly localized and controlled Li‐ion delivery for precise inhibition of neural activity at substantially reduced dosages [113]. These examples highlight the unique ability of biointegrated batteries to achieve spatiotemporally controlled metal─ion delivery and therapeutic intervention. Electrochemical by‐product therapy based on biointegrated batteries is a multimodal intervention platform. Although these systems have considerable clinical potential, their multitarget mechanisms present complex challenges in terms of safety, stability, and therapeutic precision. For example, variations in metabolism, proliferation, and apoptosis across different cancer cell types can significantly affect their responsiveness to ROS, gases, metal ions, and other electrochemical products. In addition, intracellular signaling pathways are crucial for determining cellular responses to electrochemical interventions, including those related to oxidative stress responses, inflammatory processes, and apoptosis mechanisms. A detailed understanding of the interactions between the cellular pathways and battery‐generated products is crucial for developing precise therapeutic strategies. Moreover, integrating advanced biotechnologies, such as gene editing and cell signaling pathway modulation, may further enhance the selectivity and efficacy of battery‐based electrochemical interventions. Precision Pharmacotherapy via Battery‐Enabled Active Drug Delivery Pharmacotherapy based on biointegrated batteries achieves precise control of drug‐release behavior through continuous electrochemical reactions within the system and controllable electrical energy output [114, 115]. This system dynamically regulates the location, timing, and dosage of drug release without altering the properties of the drug, improving therapeutic efficacy and expanding its potential applications in disease diagnosis, prevention, and treatment. The mechanism of action relies on electrochemical activation and battery‐enabled drug delivery. Modulating electrical parameters, such as current and voltage, enables time‐controlled, quantitatively precise, and targeted drug delivery. Pharmacotherapy is a key technology in biointegrated battery therapy. By leveraging electrochemical activation and programmed delivery, biointegrated batteries can provide an innovative platform for developing precise, dynamic, and adjustable smart drug delivery systems. Electrochemically Triggered Drug Delivery Systems In biointegrated battery‐enabled drug delivery systems, electroactive materials, such as conductive polymers, achieve controlled drug release through redox‐responsive mechanisms. These polymers can incorporate ionic drugs as dopants into their frameworks during oxidation and release them via electrochemical reduction, enabling precise dosing synchronized with the battery operation (Figure 7a). Zn‐PEDOT batteries possess distinct advantages, including acid‐driven propulsion, high drug‐loading capacity, autonomous drug release, and biodegradability. They demonstrated minimal inflammatory response and low cell apoptosis, suggesting excellent biocompatibility for drug delivery applications [116, 117]. Similarly, Mg‐based primary batteries achieve precise and controllable drug release by regulating the electrochemical reaction rates [118, 119]. Recent electrode designs have integrated drug reservoirs directly with electrochemical reaction functions. This strategy eliminates the traditional interface between electrodes and drug reservoirs in iontophoresis patches, improves battery efficiency, and enables precise control of drug delivery timing and dosage. Electroactive polymers (e.g., viologen and its derivatives, conductive polymers) with dual functions of energy storage and drug loading have been used as integrated drug‐loaded cathodes in biointegrated batteries. Their redox properties trigger embedded drug release during battery operation. This approach presents considerable potential for treating chronic skin diseases [120, 121, 122]. Mechanisms and device architectures of biointegrated battery‐powered precision pharmacotherapy. (a) Electrochemically activated drug delivery. Oxidation/reduction (Ox/Re) reactions during battery discharge activate on‐demand preloaded drug release from the electrode interface. (b) Iontophoresis. EFs generated by the biointegrated battery are used to transport therapeutic drugs from the drug reservoir into deep tissues. (c) Delivery via electrochemical corrosion. A sacrificial anode metal serves as a gate for the drug reservoir, where accelerated electrochemical corrosion enables precise encapsulated drug delivery. (d) Electrothermally activated delivery. Joule heating from the biointegrated battery causes a localized temperature increase, triggering drug release from thermosresponsive carriers. Created in BioRender. Zhou, Y. (2026) https://BioRender.com/048gj68. Spatiotemporally Controlled Electromotive Drug Delivery Using Biointegrated Batteries Ionophoresis utilizes EF or a chemical gradient to drive drug molecules across cell membranes or tissue barriers to enhance drug permeability [123]. (Figure 7b) Recently, wearable patches integrating biointegrated batteries with iontophoresis have advanced rapidly owing to their simplicity and ease of use. These patches generate safe voltages below 2 V through optimized electrochemical reactions to drive efficient drug delivery. Several wearable battery‐powered iontophoresis patches have been commercialized and approved by the US Food and Drug Administration (FDA). For instance, the IontoPatch designed by Travanti Medical uses a Zn─AgCl battery as a built‐in power source, with an output voltage of approximately 0.38 V. The Zn─AgCl battery generates an average current density of 0.10–0.58 mA/cm2, enabling controlled release of various drugs [124]. In addition, Zn─Ag and Zn─Cu primary batteries have been explored to enhance transdermal drug delivery [116, 125]. Sputtering Mg and Fe onto a polylactic acid film forms a primary battery that accelerates wound healing by promoting continuous growth factor secretion and delivery in a body fluid environment [126]. Recently, Rogers et al. designed a light‐controlled self‐powered drug delivery system that uses an external light source to illuminate an implantable wavelength‐sensitive phototransistor, triggering electrochemical metal anode corrosion and enabling drug release. This technology successfully delivered lidocaine to rats, demonstrating its potential for use in pain management (Figure 7c) [127]. Electrothermal activation utilizes the heat generated by a battery to control drug release, typically using thermosensitive materials to regulate release rate and dosage. A stretchable electronic patch combining lithium‐ion batteries, resistive heaters, and dressings has also been developed for on‐demand electrothermal drug release to effectively prevent tumor recurrence [128]. This approach has also demonstrated effectiveness in controlled insulin delivery (Figure 7d) [129]. Biointegrated batteries with high biocompatibility, long‐term stability, and stimuli‐responsive drug release have emerged as promising platforms for smart drug delivery systems. In contrast, traditional drug delivery systems rely on passive mechanisms, such as diffusion, dissolution, or osmotic pressure, which are constrained by material properties and environmental factors (e.g., pH and temperature) and lack dynamic control [130]. Although biointegrated batteries can actively regulate drug release through redox reactions, ionophoresis, or electrothermal effects, conventional constant voltage or current modes remain insufficient to fully meet the dynamic therapeutic demands. Moreover, the migration behaviors of different drug molecules (e.g., hydrophilic/hydrophobic and ionic drugs) vary significantly under different electrochemical conditions, which may lead to asynchronous or suboptimal drug release. Consequently, future research should focus on integrating closed‐loop feedback control with micro‐/nanofabrication techniques to construct multichannel intelligent delivery systems featuring individually addressable electrode arrays. In parallel, integrating implantable biosensors with intelligent algorithms to monitor biomarkers in real time and dynamically adjust the battery output has potential for realizing on‐demand, personalized drug delivery. Although biointegrated batteries have demonstrated promising therapeutic efficacy across diverse disease models, a systematic evaluation of this rapidly expanding field remains challenging owing to the wide variation in therapeutic strategies and device designs. Here, Table 1 summarizes representative biointegrated batteries reported to date, including electrode materials, device configurations, electrochemical performance, therapeutic functions, targets, validation methods, applications, and limitations. Despite the application‐specific design requirements, achieving a balance between therapeutic efficacy and biosafety remains a central challenge for biointegrated battery‐based electroceuticals. TABLE 1Features, functions, applications, and limitations of biointegrated battery‐based electroceuticals.Therapeutic OutputAnode//CathodeDevice configurationPerformanceTherapeutic targetValidationApplicationLimitationsRefs.EF Li4Ti5O12‐CNT// LiMn2O4‐CNT Miniaturization 0.65 V, 570 nAh/µL Cardiac electrophysiologyCells, isolated mouse heartsCardiac diseaseUV light for activation[89]EFZn//CNT‐PtTubular231.4 mWh/cm3 Schwann cell, axon growthCell, ratNerve repairDegradability, safety[80]EFInGa3//CuPatch—Cardiac electrophysiologyCell, ratWound, rat cardiac pacing modelLong‐term biosafety of liquid metals.[88]EFZn//MnO2 Patch1.5 V, 1.37 mAh/cm2 Fibroblast‐Directed Migration PathwayRatWound healingStructural compatibility[71]EFCS, CSA, HECTubular150 mVSchwann cells, Axon regeneration signalsCell, ratNerve repairIon gradient stability.[131]EFZn//MnO2 PatchPre‐programmed output—HumanNeurostimulation, chronic wound, drug deliveryTreatment mode lacks dynamic adjustment capabilities[132]EFMg //MoO3 Miniaturization0.64 mACardiac electrophysiologyEx vivo pig/human, in vivo mouse/rat/dogPacemakersLight intensity and location[62]EFMg//MoPatch0.94 V, day 1Cell proliferationCell, mouseGastrointestinal injuryLong‐term adhesion[75]EFMg//FeMnPatch—Schwann cell, axon growthRatnerve repair,Electrode stability[63]EFZn//MoPatch1.2 V, day 1MSCs migration and elastin secretionCell, ratsPelvic Organ ProlapseLong‐term survival of stem cells[133]EFMg//MoPatch1.2−1.3 VFibroblast migration pathwaysRatWound healingElectrolyte stability[134]By‐product Ti2AlN//Ti2N Miniaturization—BiomoleculesMouseAntitumorUnclear target and metabolic pathways[98]By‐productMg//MXene (air)Patch0.82 VMacrophage polarization, PI3K/AktRatWound healingO2‐rich environment is required for the air cathode[25]By‐productCu//SnMiniaturization—Bacterial respiratory chain/ferroptosisMouseAntimicrobial, antitumorlong‐term toxicity of Sn[111]By‐productMg//CPatch 1.9 V Fibroblast Migration Pathways, Macrophage PolarizationCell, ratAntimicrobial, Wound healingElectrolyte stability[135]By‐productZn//PEDOT:PSSPatch4.7 mAh cm−2 Oxidative damage, Fibroblast migration pathwaysCell, mouseWound healingCathode regeneration process relies on external oxygen.[73]By‐productZn//viologenPatch6.42 mAh cm−2 Fibroblast proliferationCell, ratWound healingCathode regeneration process relies on external oxygen.[72]By‐productZn//MnO2 Tubular244.0 mAh/gBMSC Osteogenic differentiation pathwayCell, ratBone defect repairCytotoxicity induced by elevated local ion concentrations[87]By‐productMg//PtMiniaturization—Mitochondrial metabolic pathways, cGAS‐STINGCell, mouse, rabbitAntitumorControllability of H2 production[102]By‐productLiFePO4//PtPatch—cAMP‐AC Neural Inhibitory PathwayCell, ratPain managementLocalized accumulation of high concentrations of Li+ [113]By‐productTi//PtPatch0.5 mAh, 23.5hROS scavenging, mitochondrial protection pathwayCell, mouseIschemia‐reperfusion injuryHydrogel mechanical and impedance deterioration[104]By‐productZn//polyimidePatch1.1 VTumor hypoxic microenvironment, cell metabolismCell, mouseAntitumorRequiring the combination with medication[97]By‐productZn//MnO2 Patch260 µAh cm−2 cGAS‐STING, Immunogenic cell death (ICD)Cell, mouseAntitumorTumor microenvironment–dependent activation[26]By‐productZn//GeMiniaturization—Osteoblast‐mediated bone formation pathway, Inhibition of osteoclast activityCell, rabbitBone defect repairLocalized accumulation of alloying elements causes cytotoxicity[112]By‐productZn//FeMiniaturization—Chronic inflammation pathway, insulin resistance pathwayMouse, ratMetabolic interventionFrequent dosing[103]By‐productZn//MnO2 Patch∼0.6 VWnt/β‐catenin signaling pathwayCell, rabbitBone regenerationBattery degradation rate[136]By‐productZn//MoPatch∼0.6 VSchwann cell proliferationCell, ratNerve injuryLong‐term metabolic safety[108]By‐productZn‐Mg//Pt (O2)Patch0.28 VMitochondrial FunctionCell, mouseAntitumorSustained in situ gas production may alter local tissue pressure[105]By‐product NaGaSn// Nanoporous gold Patch2.6 µW/cm2, 1.3 V—RatPower sourceBiosafety[38]By‐productMg//PPyPatch∼2.5 µA, 24hTGF‐𝛽/Smad pathway, macrophage polarizationCell, mousePhotoaging wrinklesPenetration depth is limited by the microneedles length[107]By‐productMn//PtMiniaturization—Mitochondrial Function, cGAS‐STINGCell, mouse, rabbitAntitumorControlled gas generation rate[106]DrugFe//AlPatch——Cell, Ex vitro intestinal, ratDrug deliveryMagnetic fields and near‐infrared light[137]DrugMg//AuPatch——Cell, mouseDrug deliveryComplex manufacturing process[138]DrugZn//PEDOTPatch8.27 mAh cm2 —Cell. mouseAtopic DermatitisDrug loading capacity[120]DrugMg//ViologenPatch3.57 mWh/cm2 —Cell. mousePsoriasisDrug capacity[118]DrugBiodegradable metal galvanic cellPatch——Cell, ratDrug deliveryLimited light penetration depth.[127]DrugMg//MoO3 Patch1.4‐1.8V—MousePsoriasisElectrochromic accuracy[139]DrugZn//CuMiniaturization—Acute lesion tissue / Neurotransmitter receptor targetsDogDrug deliveryComplex device structure[140] Note: CS, CSA, HEC: chitosan, chondroitin sulfate, hydroxyethylcellulose; TGF‐𝛽: transforming growth factor. Features, functions, applications, and limitations of biointegrated battery‐based electroceuticals. Li4Ti5O12‐CNT// LiMn2O4‐CNT 0.65 V, 570 nAh/µL Ti2AlN//Ti2N 1.9 V 1.9 V NaGaSn// Nanoporous gold Note: CS, CSA, HEC: chitosan, chondroitin sulfate, hydroxyethylcellulose; TGF‐𝛽: transforming growth factor. Challenge and Outlook Biointegrated battery‐based electroceuticals have caused a profound transformation of traditional electrotherapy technologies, shifting from passive energy delivery to active therapeutic interventions. Their advantage lies in the integration of adjustable EFs with localized electrochemical reactions to achieve precise disease microenvironment regulation. Using well‐controlled EFs, these systems can regulate cellular behavior, promote wound healing, guide nerve repair, accelerate bone regeneration, and enable reliable cardiac pacing and defibrillation. In addition to ES, electrochemical therapy within specific pathological microenvironments can be achieved via controlled ion release, localized ROS generation, or in situ production of therapeutic gases. Such battery‐enabled platforms further enhance drug penetration and bioavailability via iontophoresis or electrochemically activated release, thereby enabling synergistic therapy. With precise spatial control and adjustable energy output, battery‐based electrocatalysts offer unique advantages for targeted therapy and intelligent medical system development. However, clinical translation remains limited by challenges in material design, the mechanistic understanding of bioelectrical interactions, and device‐level system integration. Therefore, future research on biointegrated batteries should focus on addressing the following key challenges to enable safe, efficient, and clinically adaptable electroceutical technologies: Miniaturization. Battery miniaturization is essential to reduce implantation trauma, minimize foreign body reactions, and enable precise, localized targeted interventions. However, reducing the size of the battery inevitably limits energy output [141]. Therefore, optimizing battery structure and electrode materials to maximize energy output within a limited volume remains a key challenge. To meet the energy demands of long‐term therapies, miniaturization must be integrated with advanced in situ charging technologies. Piezoelectric and triboelectric effects can be used to convert in vivo biomechanical energy into electrical energy [142]. Wireless power transfer technologies (e.g., alternating magnetic‐field‐based electromagnetic induction and radio frequency [RF] energy harvesting) provide a technical foundation for safe and reliable wireless power supplies [143]. Deeply integrating these complementary charging approaches with miniaturized biointegrated batteries is expected to advance their long‐term operation and clinical translation. Miniaturization. Battery miniaturization is essential to reduce implantation trauma, minimize foreign body reactions, and enable precise, localized targeted interventions. However, reducing the size of the battery inevitably limits energy output [141]. Therefore, optimizing battery structure and electrode materials to maximize energy output within a limited volume remains a key challenge. To meet the energy demands of long‐term therapies, miniaturization must be integrated with advanced in situ charging technologies. Piezoelectric and triboelectric effects can be used to convert in vivo biomechanical energy into electrical energy [142]. Wireless power transfer technologies (e.g., alternating magnetic‐field‐based electromagnetic induction and radio frequency [RF] energy harvesting) provide a technical foundation for safe and reliable wireless power supplies [143]. Deeply integrating these complementary charging approaches with miniaturized biointegrated batteries is expected to advance their long‐term operation and clinical translation. Closed‐loop intelligent control systems. Current biointegrated batteries operate under open‐loop control, which limits their ability to adapt to dynamic changes in diseased microenvironments. Future research should focus on closed‐loop intelligent systems that integrate sensing, decision making, and therapeutic execution [144]. By incorporating stimuli‐responsive materials into battery electrodes, these platforms can monitor changes in microenvironment signals (e.g., pH, ROS, and inflammatory factors) in real time. The collected data can be processed using flexible microelectronics to adjust the battery discharge mode or drug release automatically, thereby optimizing the therapeutic output. Integration with artificial‐intelligence‐driven predictive models may further enable the early detection of abnormal responses and automated corrective interventions. Such closed‐loop bioelectronic systems enable tightly coupled sensing and therapy, thereby providing a powerful platform for telemedicine and chronic disease management. Closed‐loop intelligent control systems. Current biointegrated batteries operate under open‐loop control, which limits their ability to adapt to dynamic changes in diseased microenvironments. Future research should focus on closed‐loop intelligent systems that integrate sensing, decision making, and therapeutic execution [144]. By incorporating stimuli‐responsive materials into battery electrodes, these platforms can monitor changes in microenvironment signals (e.g., pH, ROS, and inflammatory factors) in real time. The collected data can be processed using flexible microelectronics to adjust the battery discharge mode or drug release automatically, thereby optimizing the therapeutic output. Integration with artificial‐intelligence‐driven predictive models may further enable the early detection of abnormal responses and automated corrective interventions. Such closed‐loop bioelectronic systems enable tightly coupled sensing and therapy, thereby providing a powerful platform for telemedicine and chronic disease management. Decoding electrochemical language. Current biointegrated battery systems largely rely on macroscopic biological outcomes; however, the quantitative relationships between electrochemical signals and cellular behavior remain poorly understood. Future research should establish quantitative links between electrochemical parameters and biological responses and elucidate how electrochemically generated ions or molecules interact with intracellular biomolecules and signaling pathways. Establishing an integrated research platform will enable deep data correlation between real‐time imaging‐captured cellular dynamic epigenetic information and molecular network changes revealed by single‐cell sequencing, thereby systematically elucidating the intrinsic relationship between electrical signal inputs and cellular response outputs. In parallel, micro‐ and nano‐interface engineering may enable the targeted regulation of subcellular structures, allowing direct intervention in specific organelles. For example, mitochondria‐targeted Zn2+ release can selectively induce apoptosis in tumor therapy while minimizing off‐target effects. Understanding how electrochemically generated species regulate enzyme activity, transcription factor binding, and DNA damage/repair processes will offer a molecular foundation for the precise regulation of cell fate using biointegrated batteries. Decoding electrochemical language. Current biointegrated battery systems largely rely on macroscopic biological outcomes; however, the quantitative relationships between electrochemical signals and cellular behavior remain poorly understood. Future research should establish quantitative links between electrochemical parameters and biological responses and elucidate how electrochemically generated ions or molecules interact with intracellular biomolecules and signaling pathways. Establishing an integrated research platform will enable deep data correlation between real‐time imaging‐captured cellular dynamic epigenetic information and molecular network changes revealed by single‐cell sequencing, thereby systematically elucidating the intrinsic relationship between electrical signal inputs and cellular response outputs. In parallel, micro‐ and nano‐interface engineering may enable the targeted regulation of subcellular structures, allowing direct intervention in specific organelles. For example, mitochondria‐targeted Zn2+ release can selectively induce apoptosis in tumor therapy while minimizing off‐target effects. Understanding how electrochemically generated species regulate enzyme activity, transcription factor binding, and DNA damage/repair processes will offer a molecular foundation for the precise regulation of cell fate using biointegrated batteries. Bioelectronic interface remodeling. Current designs for biointegrated batteries focus on minimizing foreign body responses. Future research should move beyond this passive approach toward actively remodeling the interface. The interface between the battery and tissue should function not as an inert barrier but as a dynamic platform that responds to microenvironmental changes and participates in disease initiation [145]. Through a molecular‐level programmable design, the electrode and electrolyte can undergo controlled degradation after energy delivery, releasing ions and molecules that regulate cellular activity and the local microenvironment. The surface structure and mechanical properties of electrodes can adapt to different stages of tissue growth, providing matching physical support and biochemical signaling. This approach integrates energy supply, controllable degradation, and therapeutic function, and requires a balance between mechanical, electrochemical, and biological properties. Establishing standardized, dynamic biocompatibility assessments will be essential for evaluating not only the safety of the battery and its byproducts but also the entire dynamic biological interactions from implantation to complete degradation. Bioelectronic interface remodeling. Current designs for biointegrated batteries focus on minimizing foreign body responses. Future research should move beyond this passive approach toward actively remodeling the interface. The interface between the battery and tissue should function not as an inert barrier but as a dynamic platform that responds to microenvironmental changes and participates in disease initiation [145]. Through a molecular‐level programmable design, the electrode and electrolyte can undergo controlled degradation after energy delivery, releasing ions and molecules that regulate cellular activity and the local microenvironment. The surface structure and mechanical properties of electrodes can adapt to different stages of tissue growth, providing matching physical support and biochemical signaling. This approach integrates energy supply, controllable degradation, and therapeutic function, and requires a balance between mechanical, electrochemical, and biological properties. Establishing standardized, dynamic biocompatibility assessments will be essential for evaluating not only the safety of the battery and its byproducts but also the entire dynamic biological interactions from implantation to complete degradation. Electrochemical genetic programming. Integrating biointegrated batteries with synthetic biology technologies enables the direct, programmable control of intracellular gene expression using precise electrochemical cues generated by batteries. The voltage, current, ion type, and pulse frequency serve as programmable inputs that convert physical stimulation into defined biological outputs in combination with engineered genetic circuits. Battery‐generated EFs activate voltage‐sensitive ion channels, triggering downstream Ca2+ signaling cascades that regulate transcription factor activity and translocation. Meanwhile, localized currents alter the membrane potential, influencing gene transcription efficiency through a phosphorylation cascade. The released metal ions can serve as inducible mediators of gene regulation, enabling in situ synthesis of therapeutic proteins such as insulin, anti‐inflammatory factors, and growth factors. The low concentrations of ROS generated by the battery can further trigger redox‐sensitive gene switches, thereby activating antioxidant or anti‐apoptotic genes. Electrochemical genetic programming transforms biointegrated batteries from passive energy sources into programmable platforms capable of regulating gene expression and controlling cell fate, metabolic pathways, and endogenous functions, offering a novel strategy for precise intervention across diverse diseases. By leveraging this mechanism, biointegrated batteries can evolve into symbiotic bioelectronics. Batteries establish bidirectional interactions that coordinate energy output, material interfaces, and information exchange. Electrical output can be programmed to synchronize with the physiological rhythms of the target organs, enabling stimulation to match the body's dynamic requirements. Integration with engineered cells enables electrochemical signals to trigger complex biological functions while sensing changes in the local microenvironment and adjusting the battery output accordingly. In parallel, the metabolic activity of the host can modulate the device behavior, forming a closed‐loop, adaptive bioelectronic network. Such symbiotic systems position biointegrated batteries as active nodes within the functional network of living organisms capable of supplementing or restoring impaired biological functions. Ultimately, this approach may shift therapeutic strategies for chronic diseases from repeated external interventions to a long‐term, seamless integration with the host organism. Electrochemical genetic programming. Integrating biointegrated batteries with synthetic biology technologies enables the direct, programmable control of intracellular gene expression using precise electrochemical cues generated by batteries. The voltage, current, ion type, and pulse frequency serve as programmable inputs that convert physical stimulation into defined biological outputs in combination with engineered genetic circuits. Battery‐generated EFs activate voltage‐sensitive ion channels, triggering downstream Ca2+ signaling cascades that regulate transcription factor activity and translocation. Meanwhile, localized currents alter the membrane potential, influencing gene transcription efficiency through a phosphorylation cascade. The released metal ions can serve as inducible mediators of gene regulation, enabling in situ synthesis of therapeutic proteins such as insulin, anti‐inflammatory factors, and growth factors. The low concentrations of ROS generated by the battery can further trigger redox‐sensitive gene switches, thereby activating antioxidant or anti‐apoptotic genes. Electrochemical genetic programming transforms biointegrated batteries from passive energy sources into programmable platforms capable of regulating gene expression and controlling cell fate, metabolic pathways, and endogenous functions, offering a novel strategy for precise intervention across diverse diseases. By leveraging this mechanism, biointegrated batteries can evolve into symbiotic bioelectronics. Batteries establish bidirectional interactions that coordinate energy output, material interfaces, and information exchange. Electrical output can be programmed to synchronize with the physiological rhythms of the target organs, enabling stimulation to match the body's dynamic requirements. Integration with engineered cells enables electrochemical signals to trigger complex biological functions while sensing changes in the local microenvironment and adjusting the battery output accordingly. In parallel, the metabolic activity of the host can modulate the device behavior, forming a closed‐loop, adaptive bioelectronic network. Such symbiotic systems position biointegrated batteries as active nodes within the functional network of living organisms capable of supplementing or restoring impaired biological functions. Ultimately, this approach may shift therapeutic strategies for chronic diseases from repeated external interventions to a long‐term, seamless integration with the host organism. Clinical translation pathway. Although biointegrated batteries have shown strong potential in fundamental research, their transition from laboratory prototypes to clinical applications remains challenging. Notably, several non‐implantable electrotherapy products based on galvanic cell technology have already been commercialized, providing important proof‐of‐concept for clinical translation. For example, IontoPatch, approved by the U.S. FDA, utilizes integrated galvanic cells to enable transdermal drug delivery. Similarly, the PowerHeal and Procellera wound dressings developed by Vomaris, as well as the JumpStart dressing produced by Arthrex for surgical incision management, all incorporate embedded Zn─Ag galvanic cell arrays [146]. Upon contact with physiological fluids, these dressings are spontaneously activated, generating microcurrents that mimic the bioelectric field of the body. Clinical studies have demonstrated that these products not only eliminate 99.99% of bacteria but also significantly accelerate cell migration and increase tissue healing rates by two to three times. In contrast, implantable, biodegradable biointegrated battery systems face substantially greater regulatory and translational challenges. These systems span the conventional boundaries between medical devices and therapeutic agents, while standardized evaluation frameworks for such hybrid technologies remain limited. Future clinical translation will require rigorous Good Laboratory Practice‐compliant evaluations, including long‐term pharmacokinetic and pharmacodynamic evaluations in large animal models. Furthermore, scalable, reproducible, and cost‐effective manufacturing processes will be essential for the eventual commercialization of implantable biointegrated batteries. Clinical translation pathway. Although biointegrated batteries have shown strong potential in fundamental research, their transition from laboratory prototypes to clinical applications remains challenging. Notably, several non‐implantable electrotherapy products based on galvanic cell technology have already been commercialized, providing important proof‐of‐concept for clinical translation. For example, IontoPatch, approved by the U.S. FDA, utilizes integrated galvanic cells to enable transdermal drug delivery. Similarly, the PowerHeal and Procellera wound dressings developed by Vomaris, as well as the JumpStart dressing produced by Arthrex for surgical incision management, all incorporate embedded Zn─Ag galvanic cell arrays [146]. Upon contact with physiological fluids, these dressings are spontaneously activated, generating microcurrents that mimic the bioelectric field of the body. Clinical studies have demonstrated that these products not only eliminate 99.99% of bacteria but also significantly accelerate cell migration and increase tissue healing rates by two to three times. In contrast, implantable, biodegradable biointegrated battery systems face substantially greater regulatory and translational challenges. These systems span the conventional boundaries between medical devices and therapeutic agents, while standardized evaluation frameworks for such hybrid technologies remain limited. Future clinical translation will require rigorous Good Laboratory Practice‐compliant evaluations, including long‐term pharmacokinetic and pharmacodynamic evaluations in large animal models. Furthermore, scalable, reproducible, and cost‐effective manufacturing processes will be essential for the eventual commercialization of implantable biointegrated batteries. Author Contributions Z.Y. led the literature collection, drafted the manuscript, and synthesized critical advancements in the field. Z.C. and Z.L.Y. contributed to the knowledge on hydrogel biomaterials and tissue engineering. D.C. has expertise in redox‐active biomaterials. X.J. contributed to refining technical accuracy and critically revised the therapeutic mechanisms. G.W. provided oversight and revisions, ensuring coherence across the interdisciplinary domains. C.W. conceptualized and organized the review and contributed extensively to the critical evaluation and manuscript revision. Funding This work is supported by the National Natural Science Foundation of China (Grant Nos. 62401223, 6233371205) and Australian Research Council Discovery Project (Grant No. ARC DP260101945). Conflicts of Interest The authors declare no conflicts of interest.